Menu
Currency
GWAS Study

New Locus for Skin Intrinsic Fluorescence in Type 1 Diabetes Also Associated With Blood and Skin Glycated Proteins.

Roshandel D, Klein R, Klein BE et al.

27207532 PubMed ID
GWAS Study Type
1359 Participants
38 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

RD
Roshandel D
KR
Klein R
KB
Klein BE
WB
Wolffenbuttel BH
VD
van der Klauw MM
VV
van Vliet-Ostaptchouk JV
AG
Atzmon G
BD
Ben-Avraham D
CJ
Crandall JP
BN
Barzilai N
BS
Bull SB
CA
Canty AJ
HS
Hosseini SM
HL
Hiraki LT
MJ
Maynard J
SD
Sell DR
MV
Monnier VM
CP
Cleary PA
BB
Braffett BH
PA
Paterson AD
Chapter II

Abstract

Summary of the research findings

Skin fluorescence (SF) noninvasively measures advanced glycation end products (AGEs) in the skin and is a risk indicator for diabetes complications. N-acetyltransferase 2 (NAT2) is the only known locus influencing SF. We aimed to identify additional genetic loci influencing SF in type 1 diabetes (T1D) through a meta-analysis of genome-wide association studies (N = 1,359) including Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) and Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR). A locus on chromosome 1, rs7533564 (P = 1.9 × 10(-9)), was associated with skin intrinsic fluorescence measured by SCOUT DS (excitation 375 nm, emission 435-655 nm), which remained significant after adjustment for time-weighted HbA1c (P = 1.7 × 10(-8)). rs7533564 was associated with mean HbA1c in meta-analysis (P = 0.0225), mean glycated albumin (P = 0.0029), and glyoxal hydroimidazolones (P = 0.049), an AGE measured in skin biopsy collagen, in DCCT. rs7533564 was not associated with diabetes complications in DCCT/EDIC or with SF in subjects without diabetes (nondiabetic [ND]) (N = 8,721). In conclusion, we identified a new locus associated with SF in T1D subjects that did not show similar effect in ND subjects, suggesting a diabetes-specific effect. This association needs to be investigated in type 2 diabetes.

1,359 European ancestry cases

Chapter III

Study Statistics

Key metrics and study information

1359
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
U.S.
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.